Cowen Starts Loxo Oncology (LOXO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Stifel Nicolaus Starts Loxo Oncology (LOXO) at Buy
September 2, 2014 6:54 AM EDTStifel Nicolaus initiated coverage on Loxo Oncology (NASDAQ: LOXO) with a Buy rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Loxo Oncology click here. For more ratings news on Loxo Oncology click here.
Shares of Loxo Oncology closed at $13.01 yesterday.
... MoreOppenheimer Starts Loxo Oncology (LOXO) at Outperform
September 2, 2014 6:28 AM EDTOppenheimer initiates coverage on Loxo Oncology (NASDAQ: LOXO) with a Outperform rating and a price target of $20.00.
Analyst Yigal Nochomovitz, Ph.D. commented, "Loxo is an early-stage biotechnology company executing a business plan for targeted cancer drugs that benefits from 1) clear precedent for... More
